Patient-reported compliance with thromboprophylaxis using an oral factor Xa inhibitor (rivaroxaban) following total hip and total knee arthroplasty.

MLA

Carrothers, Andrew D., et al. “Patient-Reported Compliance with Thromboprophylaxis Using an Oral Factor Xa Inhibitor (Rivaroxaban) Following Total Hip and Total Knee Arthroplasty.” The Journal of Arthroplasty, vol. 29, no. 7, July 2014, pp. 1463–67. EBSCOhost, https://doi.org/10.1016/j.arth.2013.02.001.

APA

Carrothers, A. D., Rodriguez-Elizalde, S. R., Rogers, B. A., Razmjou, H., Gollish, J. D., & Murnaghan, J. J. (2014). Patient-reported compliance with thromboprophylaxis using an oral factor Xa inhibitor (rivaroxaban) following total hip and total knee arthroplasty. The Journal of Arthroplasty, 29(7), 1463–1467. https://doi.org/10.1016/j.arth.2013.02.001

Chicago

Carrothers, Andrew D, Sebastian R Rodriguez-Elizalde, Benedict A Rogers, Helen Razmjou, Jeffrey D Gollish, and John J Murnaghan. 2014. “Patient-Reported Compliance with Thromboprophylaxis Using an Oral Factor Xa Inhibitor (Rivaroxaban) Following Total Hip and Total Knee Arthroplasty.” The Journal of Arthroplasty 29 (7): 1463–67. doi:10.1016/j.arth.2013.02.001.